Amplitude, Inc. logo AMPL - Amplitude, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 8
HOLD 4
SELL 0
STRONG
SELL
0
| PRICE TARGET: $10.60 DETAILS
HIGH: $12.00
LOW: $10.00
MEDIAN: $10.00
CONSENSUS: $10.60
UPSIDE: 21.28%

Stock News

Amplitude to Host Second Quarter 2026 Earnings Webcast on August 5, 2026

Amplitude to Host Second Quarter 2026 Earnings Webcast on August 5, 2026

SAN FRANCISCO--(BUSINESS WIRE)---- $AMPL--Amplitude, Inc. (Nasdaq: AMPL), the leading AI analytics platform, today announced that it will release its financial results for the second quarter of 2026 after market close on Wednesday, August 5, 2026. Amplitude will host a video webcast that day at 2:00 PM PT to discuss its financial results and provide its financial outlook for the third quarter and full year 2026.The webcast will be available on the Investor Relations section of Amplitude's website at inves.

Jul 15, 2026 05:00 AM businesswire.com
Amplitude: The Market Is Starting To Catch On To Improving Fundamentals

Amplitude: The Market Is Starting To Catch On To Improving Fundamentals

Amplitude offers a compelling opportunity as capital rotates from large-cap AI stocks to smaller-cap names in H2 FY26. AMPL's high-teens revenue and ARR growth, expanding margins, and improving net expansion rates highlight resilient fundamentals amid macro and AI-driven shifts. Backlog growth exceeding 30% y/y and a blue-chip customer base underscore AMPL's strategic relevance and customer stickiness.

Jul 02, 2026 12:58 AM seekingalpha.com
AMPL Investors Have Opportunity to Join Amplitude, Inc. Fraud Investigation with the Schall Law Firm

AMPL Investors Have Opportunity to Join Amplitude, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amplitude, Inc. ("Amplitude" or "the Company") (NASDAQ: AMPL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Jun 11, 2026 08:00 AM prnewswire.com (Hide legal announcements)
AMPL Investors Have Opportunity to Join Amplitude, Inc. Fraud Investigation with the Schall Law Firm

AMPL Investors Have Opportunity to Join Amplitude, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amplitude, Inc. ("Amplitude" or "the Company") (NASDAQ: AMPL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Jun 08, 2026 05:06 AM prnewswire.com (Hide legal announcements)
2026 CPO Insights Report Predicts Product Managers Will Disappear by 2030

2026 CPO Insights Report Predicts Product Managers Will Disappear by 2030

A global survey of 1,500+ Chief Product Officers offers data on the future of product leadership and how organizations can create and deliver value at the speed of AI. SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Products That Count, the world's largest nonprofit community of product leaders, and  Mighty Capital, a venture capital firm specializing in product-led investing, today released the fifth annual Chief Product Officer ("CPO") Insights Report.

May 27, 2026 05:00 AM prnewswire.com
BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem

BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem

CHARLEVOIX, Mich.--(BUSINESS WIRE)--BioStar Capital, a venture capital firm focused on transformative medical technologies, has announced a landmark pre-FDA exit of Amplitude Vascular Systems, Inc. (AVS), a medical technology company that created a next-generation hydraulic intravascular lithotripsy (IVL) platform to treat calcified peripheral arterial disease. Upon acquiring AVS for up to $835 million, Stryker (NYSE:SYK), a global leader in medical technologies, called the deal a milestone in.

May 19, 2026 01:30 AM businesswire.com

Price Targets